Authors:
Reubinoff BE. Grubstein A. Meirow D. Berry E. Schenker JG. Brzezinski A.
Institution
Department of Obstetrics/Gynecology, Hadassah Medical Center,Jerusalem 91120; Israel.
Title:
Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women (1995-2109b).
Source:
Fertility and Sterility. Vol 63(3) (pp16-521), 1995.
Abstract:
Objectives:
To determine prospectively whether the use of low-dose
Estrogen oral contraceptives (OC) is associated with changes in weight, body composition, or fat distribution.
Design:
Anthropometric measurements were performed in 49 healthy young (16 to 21 years old) women before commencement of OC use (30 mug ethinyl estradiol [EE2] plus 75 mug gestodene) and after three and six treatment cycles. Thirty one age and weight-matched women who were not using OC served as controls.
Setting:
Outpatient gynecological clinic of Hadassah Medical Center, a tertiary level hospital, and the 'Shilo' voluntary service for the prevention of unwanted pregnancy.
Settings, Design and Main Outcome Measures:
Anthropometric measurements included body mass index (BMI), waist- to-hip girth ratio, and body composition (the percentage of body fat and water), estimated by mean of infrared interactance.
Results:
In the group of OC users, baseline BMI, percent fat, percent water, and waist-to-hip girth ratio were 21.1 +/- 0.32 (kg/m2), 23.8% +/- 0.63%, 57.4% +/- 0.39%, and 0.73 +/- 0.01, respectively, and did not change significantly after six cycles (20.6 +/- 0.41 [kg/m2], 23.9% +/- 0.57%, 58.1% +/- 0.49%, and 0.72 +/- 0.03, respectively). These measurements were not significantly different when compared with the nonusers. Fifteen OC users (30.6%) gained weight (>0.5 kg). Weight gain was due to a significant accumulation of fat (from 22.5% +/- 1.1% to 25.6% +/- 0.74%), whereas the percentage of body water remained stable. The waist-to hip girth ratio also was not changed significantly. Similarly, 11 nonusers (35.4%) gained weight because of similar nonabdominal fat accumulation. Ten OC users (20.4%) lost weight (57 kg +/- 1.51 to 55.4 +/- 1.47 [mean +/- SEMI) and 6 nonusers (19.3%) also lost weight (59 kg +/- 1.42 to 57.3 +/- 1.92). In both groups the loss of weight was not associated with significant change in body composition.
Conclusions:
The use of low-dose OC (EE2 plus gestodene) was not associated with overall impact on weight, body composition, or fat distribution. However, when weight gain did occur during OC use, it was due to increase in body fat and not in volume of body water, and it was not associated with changes in fat distribution.
Please click on the required question.
- 1 What is an oral contraceptive?
- 2 How popular are oral contraceptive pills?
- 3 What are the benefits of the combined oral contraceptive pill?
- 4 Will the combined oral contraceptive pill improve my periods?
- 5 Could the combined oral contraceptive pill change my libido (sex drive)
- 6 What are the risks of taking combined oral contraceptive pills?
- 7 What side effects could I have whilst taking the combined oral contraceptive pill?
- 8 What is the effect of the combined oral contraceptive pill on body weight?
- 9 Will the combined oral contraceptive pill increase my vaginal discharge?
- 10 Does the combined oral contraceptive pill increase the chance of pelvic infections?
- 11 What is the relationship between the combined oral contraceptive pill and fibroids?
- 12 Could a combined oral contraceptive pill increase my blood pressure?
- 13 Do combined oral contraceptive pills have any effect on the blood?
- 14 What is the relationship between the combined oral contraceptive pill and thromboembolism?
- 15 What is the relationship between the combined oral contraceptive pill and heart attacks?
- 16 What is the relationship between the combined oral contraceptive pill and strokes?
- 17 Does the combined oral contraceptive pill affect the breasts?
- 18 Could I feel depressed as a result of taking the combined oral contraceptive pill?
- 19 What is the relationship between the combined oral contraceptive pill and cancer of the ovary?
- 20 What is the relationship between the combined oral contraceptive pill and cancer of the uterus?
- 21 What is the relationship between the combined oral contraceptive pill and cancer of the cervix?
- 22 What is the relationship between the combined oral contraceptive pill and cancer of the breast?
- 23 Family Planning Support Groups.
- 24 Support Groups.
Thank you for choosing to visit us.
This is the personal website of David A Viniker MD FRCOG, Consultant Obstetrician and Gynaecologist at Whipps Cross University Hospital, London - Specialist Interests - Reproductive Medicine including Infertility, PCOS, PMS, Menopause and HRT.
I do hope that you find the answers to your women's health questions in the patient information and medical advice provided.














